|
@peterbachmd | |||||
|
Graphic labeled the 'Reward Box' to enable the double entendre sub-header in the title. But also, we want policymakers to in fact 'think inside the box'. The market is a policy construct, it is not 'free'. The industry sees it all of a piece, policy makers should too.
|
||||||
|
||||||
|
|
Peter B. Bach, MD
@peterbachmd
|
29. sij |
|
Just out @NEJM from @DhruvKhullar et al. The structure of rewards (and costs) in pharmaceutical drug development. We introduce the 'reward box' interactive graphic to see how the elements interplay, how specific policies affect it. nejm.org/doi/full/10.10…
|
||
|
||
|
|
Peter B. Bach, MD
@peterbachmd
|
29. sij |
|
Here's a link to the interactive graphic: nejm.org/doi/full/10.10…
|
||
|
|
||
|
|
Peter B. Bach, MD
@peterbachmd
|
29. sij |
|
And here is a sample of 3 policies we describe and how they alter the Reward Box shape and thus the risk and reward of developing particular types of drugs: pic.twitter.com/lJd213pOVo
|
||
|
|
||
|
Pierre Bedard
@PRB51
|
30. sij |
|
The market is free
It is possible for a competitor to invent a better drug
And succeed
Box is wide open, market is dynamic
|
||
|
|
||
|
Usuari@ tweeter
@Musicaypaz501
|
30. sij |
|
Pharma market is not “free” but monopoly-based business model.
The story of Allergan shows how corporate power harms public health. It shows the harm produced by incentives in a monopoly-based business model.
citizen.org/article/by-any…
|
||
|
|
||